News 2025-05-22
Porton Advanced Announces Collaboration with TongEYE to Accelerate Development of iPSC-RPEC transplantation therapy
Suzhou, China, May 15, 2025 - Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with TongEye Medical Technology (TongEYE)，an innovator focusing on cell therapy drugs for ophthalmic diseases. Porton Advanced will provide comprehensive CDMO services to support iPSC-derived retinal pigment epithelium cell (RPEC) therapy program, including CMC development and IND application assistance, to accelerate the therapy development progress.
The iPSC-RPEC transplantation therapy has demonstrated significant potential in addressing blinding eye diseases such as age-related macular degeneration (AMD). TongEYE has established highly efficient and proprietary induction method for differentiation through pioneering work in retinal disease mechanisms and innovative therapies. This collaboration leverages Porton Advanced’s extensive expertise in iPSC and cell therapy to provide end-to-end CDMO services encompassing iPSC reprogramming and cell banking, process optimization for RPE-directed differentiation, GMP manufacturing of RPE cells, rigorous quality studies, and IND application support.
“We are pleased to partner
with Porton Advanced, a leading CDMO with proven
track records,” said Dr. Guo-Tong Xu, Founder and Chief
Scientist of TongEYE. “Their CDMO capabilities and project
experience in iPSC will significantly accelerate our ophthalmic cell therapy
development program to benefit patients sooner.”
Andrew Chen, CFO of Porton Advanced, commented: “TongEYE’s R&D team has developed a robust RPE differentiation method and the products have been showing safety and functionality in preclinical studies. Through this collaboration, we will combine our iPSC-CMC expertise with their innovative platform to overcome key technical challenges in iPSC-based therapy development. Porton Advanced will integrate the international R&D expertise and rigorous quality systems and provide comprehensive support to advance this promising treatment globally."
About TongEYE
TongEye Medical Technology (Ningbo) Co., Ltd. was established in October 2023, focusing mainly on the development and production of cell therapy drugs for ophthalmic diseases. In November, the company completed its angel round of financing. The company has multiple research and development pipelines. Among them, the key project of transplanting unique naive RPE cells derived from iPSCs for the treatment of dry retinal degeneration has achieved significantly better therapeutic effects in animal models compared with matureRPE cells. The established highly efficient induction and differentiation method with independent intellectual property rights has shortened the traditional differentiation cycle from 120 to 150 days to just 25 days, significantly reducing costs and improving accessibility. This brings hope for vision improvement to hundreds of millions of patients with dry retinal degeneration worldwide.
About Porton Advanced
Porton Advanced Solutions is a subsidiary of
the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in
Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end
CDMO solutions for ATMPs. We offer services from cell banking, process, and
analytical method development, cGMP production to fill & finish, covering
different stages of drug development from early research, IITs, Investigational
New Drug (IND) applications, clinical trials, New Drug Applications (NDA), to
commercialization.
Others
More
News 2025-05-22
Porton Advanced Announces Collaboration with Hualong Biological to Accelerate MATC Cell Therapy Development for Solid Tumor Treatment Breakthroughs
Suzhou, China, May 12, 2025 –Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Hualong Biological，an innovator in novel cancer therapeutics.
News 2025-05-16
Join Us at Chemspec Europe 2025 in June
As a benchmark exhibition in Europe, Chemspec Europe 2025 focuses on customized chemical solutions and innovative technologies. With its highly specialized positioning, the exhibition has become a core platform for global industry elites to connect resources and expand business networks. The exhibition, which covers the entire industry chain of pharmaceuticals, electronic chemicals, agricultural chemicals and other fields, is not only a hub for technology and knowledge exchange, but also an efficient channel for companies to explore the international market.
